Skip to main content

Table 2 Baseline characteristics of included studies

From: The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review

 HannaH 2015PrefHer 2017MetaspHer 2017
 Trastuzumab SC (n = 294)Trastuzumab IV (n = 297)n = 483n = 113
DesignRCT RCT, crossoverRCT, crossover
Follow-up52–172 weeks 24 weeks18 weeks
Age (years)50 (25–81)50 (24–77)53 (27–83)59 (35–85)
Body weight (kg)68 (39–126)66 (42–137)66 (41–117)70 (46–110)
Breast cancer subtype   
Ductal272 (92.8%)273 (91.9%)Not specified70 (87.5%)
Lobular12 (4.1%)17 (5.7%) 3 (3.8%)
Other9 (3.1%)7 (2.4%) 6 (7.5%)
Ductal + other00 1 (1.3%)
Estrogen receptor status   
Negative140 (47.6%)148 (49.8%)168 (34.8%)43 (38.1%)
Positive154 (52.4%)148 (49.8%)309 (64%)57 (50.4%)
Unknown01 (0.3%)6 (1.2%)13 (11.5%)
Nodal status   
Negative71a, b (24.2%)62a (20.9 %)229 (49.04%)cNot specified
Positive222a, b (75.8%)235a (88 %)227 (48.61%)c 
Unknown0011 (2.36%)c 
Tumor stage   
T0005 (1%)Not specified
T119 (6.5%)d23 (7.9%)d204 (42.2%) 
T2129 (44%)d130 (43.8%)d208 (43.1%) 
T352 (17.7%)d49 (16.5%)d37 (7.7%) 
T493 (31.7%)d95 (32%)d25 (5.2%) 
Unknown004 (0.8%) 
  1. aClinical nodal status, bn = 293, cn = 467, dclinical tumor stage